Aggressive Progression of High Programmed Death-Ligand 1 (PD-L1) Non-small Cell Lung Cancer Presenting as Life-Threatening Esophageal Obstruction: A Case of Food Impaction Secondary to Subcarinal Lymph Node Compression
Niroshan Ranjan, Yaman Dalati, Vidushan Sabanathan, Thanujan Thangadurai

TL;DR
An elderly woman with high PD-L1 lung cancer experienced rapid disease progression and severe esophageal blockage during immunotherapy, requiring urgent medical intervention.
Contribution
This case highlights the paradoxical aggressive progression of high PD-L1 NSCLC and challenges in managing immune checkpoint inhibitor resistance.
Findings
High PD-L1 expression does not ensure immunotherapy response and may correlate with aggressive disease progression.
Subcarinal lymph node enlargement can cause life-threatening esophageal obstruction requiring urgent endoscopic intervention.
Gastrostomy tube insertion is a critical palliative measure for malignant esophageal obstruction.
Abstract
Dysphagia secondary to esophageal obstruction is a rare but clinically relevant presentation in the setting of non-small cell lung cancer (NSCLC). While pembrolizumab demonstrates efficacy in metastatic NSCLC with high programmed death-ligand 1 (PD-L1), diagnostic challenges in distinguishing pseudoprogression from true progression and paradoxical disease progression pose a clinical challenge, highlighting complexities inherent in immune checkpoint inhibitor resistance mechanisms. We present the case of an 82-year-old Caucasian woman with a diagnosis of stage IV NSCLC with extremely high PD-L1 expression who developed accelerated disease progression on pembrolizumab monotherapy. Following 11 cycles of immunotherapy, the patient developed life-threatening esophageal obstruction due to a massively enlarged subcarinal lymph node, causing significant extrinsic compression. This resulted in…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Immunotherapy and Biomarkers · Lung Cancer Treatments and Mutations · Esophageal Cancer Research and Treatment
